PSMA expression on circulating tumor cells in men with mCRPC increases upon disease progression despite treatment with novel antiandrogens.
Investigators characterized practice patterns in the first-line treatment of nonmetastatic castration-resistant prostate cancer using real-world data.
Phase 3 results appear to support intensification of ADT in patients with biochemically recurrent prostate cancer.
Longer prostate cancer-specific survival seen for specific subgroups, including those with the CYP1A2 AA genotype.
Of 4 prototypes assessed, participants preferred meter as having the best gist comprehension and emoji as having the highest verbatim comprehension.